EXPLANATORY NOTE
This Amendment No. 8 amends the Schedule 13D (as previously amended, the “Schedule 13D”), filed with the U.S. Securities and Exchange
Commission (the “SEC”) by BridgeBio Pharma, Inc. (“BridgeBio”) and its predecessor and wholly-owned subsidiary, BridgeBio Pharma LLC, relating to the Common Stock, par value $0.001 per share (“Eidos Common
Stock”), of Eidos Therapeutics, Inc., a Delaware corporation (“Eidos”), whose principal executive offices are located at 101 Montgomery Street, Suite 2000, San Francisco, California 94104. Except as specifically set forth
herein, the Schedule 13D remains unmodified.
All capitalized terms used in this Amendment No. 8 but not defined herein shall have the meanings
ascribed thereto in the Schedule 13D.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following:
On October 5, 2020, Eidos, BridgeBio, Globe Merger Sub I, Inc., a Delaware corporation and an indirect wholly owned subsidiary of
BridgeBio (“Merger Sub”), and Globe Merger Sub II, Inc., a Delaware corporation and an indirect wholly owned subsidiary of BridgeBio (“Merger Sub II”), entered into an Agreement and Plan of Merger (the
“Merger Agreement”), providing for, on the terms and subject to the conditions therein, (i) the merger of Merger Sub with and into Eidos (the “Initial Merger”), with Eidos surviving the Initial Merger, and
(ii) thereafter, the merger of Eidos with and into Merger Sub II (the “Subsequent Merger” and, together with the Initial Merger, the “Mergers”), with Merger Sub II surviving as an indirect wholly owned
subsidiary of BridgeBio.
The Merger Agreement has been unanimously approved by BridgeBio’s Board of Directors and was approved by
Eidos’ Board of Directors based upon the unanimous recommendation of a special committee of independent directors of Eidos.
Under
the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Initial Merger (the “Effective Time”), each share of Eidos Common Stock issued and outstanding immediately prior to the
Effective Time (subject to certain exceptions) will be converted into the right to receive, at the election of each stockholder of Eidos, (i) 1.85 shares of BridgeBio’s common stock, par value $0.001 per share (“BridgeBio Common
Stock”), or (ii) $73.26 in cash ((i) and (ii) collectively, the “Merger Consideration”), subject to proration as necessary to ensure that the aggregate amount of the cash portion of the Merger Consideration is no
greater than $175 million.
The Mergers are subject to certain approvals of Eidos stockholders and BridgeBio stockholders, and other
customary closing conditions.
Upon completion of the Mergers, shares of Eidos Common Stock currently listed on The Nasdaq Global Select
Market (“Nasdaq”) will cease to be listed on the Nasdaq and will subsequently be deregistered under the Securities Exchange Act of 1934, as amended.
The foregoing description of the Merger Agreement is not intended to be complete and is qualified in its entirety by reference to the full
text of the Merger Agreement, which is attached as Exhibit 1 and is incorporated herein by reference.
Except as set forth in this
Schedule 13D and in connection with the Mergers described above, BridgeBio does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on
the factors discussed herein, BridgeBio may change its purpose, change its intentions with respect to previous plans or formulate different plans or proposals with respect thereto at any time.
2